Emergent BioSolutions (EBS) Reports Q3 results; updates guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.43 +5.24%
EPS Growth %: -31.3%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -31.3%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 Revenue for the quarter at $271 million versus the consensus estimate of $237.43 million.
GUIDANCE:
Emergent BioSolutions sees FY2023 revenue of $1-1.1 billion, versus the consensus of $1.04 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
- Qualcomm expects $40bn in non-handset revenue by fiscal 2029
- H.B. Fuller (FUL) Tops Q2 EPS by 3c; Offers Outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
